Introduction {#s1}
============

Chronic inflammation and bone destruction are frequently associated due to complex interactions between activated immune cells and progenitors of bone-resorbing osteoclasts (OCLs). While they have long been attributed to the sole effect of immune cells on osteoclastogenesis, recent evidences demonstrated that these interactions are reciprocal ([@bib7]; [@bib20]; [@bib24]; [@bib27]). Indeed, OCLs are monocytic cells responding to immune signals and beside bone resorption, they present antigens and activate T cells ([@bib31]). However, to date, the mechanisms that reciprocally link inflammation and bone destruction remain poorly understood.

OCLs are long-lived multinucleated cells arising from bone marrow (BM) progenitors ([@bib4]; [@bib21]; [@bib22]). However, in inflammation, they also arise from inflammatory Ly6C^hi^ monocytes (MNs) ([@bib1]; [@bib48]) and dendritic cells (DCs) including in vivo ([@bib55]; [@bib20]; [@bib33]; [@bib44]; [@bib31]). Furthermore, OCLs permanently fuse with MNs and undergo fission to maintain their nuclei number ([@bib22]). We and others showed that depending on their origin and environment, OCLs induce different T cell responses. In steady state or when derived from BM MNs of healthy mice, OCLs activate regulatory CD4^+^ and CD8^+^ T cells (tolerogenic-OCLs/t OCLs) ([@bib20]; [@bib24]), whereas when derived from DCs or during inflammation, they induce TNFα-producing CD4^+^ T cells (inflammatory-OCLs/i-OCLs) ([@bib20]; [@bib31]). Thus, according to their origin and environment, OCLs are heterogeneous and initiate different immune responses. However, the full contribution of i-OCLs to inflammatory bone loss remains to be elucidated.

Recently, we identified the fractalkine receptor Cx3cr1 as a marker identifying i-OCLs ([@bib20]). Cx3cr1 is expressed by OCL precursors and mediates their BM recruitment by Cx3cl1-producing endothelial cells and osteoblasts ([@bib17]; [@bib18]; [@bib25]; [@bib35]). During osteoclastogenesis, the level of expression of *Cx3cr1* decreases and is very low in t-OCLs ([@bib19]; [@bib25]). However, in inflammatory conditions, *Cx3cr1* remains expressed in about 25% of i-OCLs ([@bib20]). Nevertheless, the role of Cx3cr1 in i-OCLs as well as the function and contribution of Cx3cr1^neg^ and Cx3cr1^+^ i-OCLs in inflammation have not yet been explored.

We addressed these questions using *Cx3cr1*^GFP^ mutant mice in which the *Gfp* gene is inserted in the second exon of the *Cx3cr1* gene ([@bib23]). Consequently, while Cx3cr1 activity is normal in wild type (WT) *Cx3cr1*^GFP/+^ mice, this protein is non-functional in *Cx3cr1*^GFP/GFP^ mice and in both mice, GFP expression allows to identify Cx3cr1-expressing cells ([@bib23]). We evaluated the consequences of *Cx3cr1* deficiency on inflammatory bone loss in vivo in ovariectomized (OVX) mice, a model where osteoclastogenesis is driven by TNF-α and RANK-L-producing CD4^+^ T cells ([@bib9]; [@bib28]; [@bib57]). These conditions are similar to those priming Cx3cr1^+^ OCLs previously described in inflammatory colitis ([@bib20]). We also compared Cx3cr1^+^ and Cx3cr1^neg^ i-OCLs as well as *Cx3cr1*-deficient i-OCLs by RNA-sequencing (RNA-seq) analysis and in vitro functional assays. We showed that Cx3cr1 deficiency does not change the bone resorption and T cell activation capacity of mature Cx3cr1^+^ i-OCLs demonstrating that the Cx3cr1 protein per se does not play a major role in these functions. Furthermore, we showed that Cx3cr1 is a marker that identifies two distinct subsets of i-OCLs (Cx3cr1^neg^ and Cx3cr1^+^) having different immune functions. Our findings unveil the heterogeneity of i-OCLs and their contribution to inflammation and bone loss. These new insights into osteoimmunology and OCL heterogeneity contribute to a better understanding of the bone microenvironment regulation and the underlying molecular processes during inflammatory bone destruction.

Results {#s2}
=======

Cx3cr1 deficiency protects against inflammatory bone loss in osteoporosis {#s2-1}
-------------------------------------------------------------------------

We addressed in vivo the participation of Cx3cr1 in inflammatory osteoclastogenesis in ovariectomized (OVX) mice. We previously showed that Cx3cr1^+^ i-OCLs increased in inflammatory colitis associated with bone destruction ([@bib20]) and we confirmed here that they also increased after ovariectomy in WT OVX mice ([Figure 1A](#fig1){ref-type="fig"}). To evaluate the implication of Cx3cr1 in OVX-induced bone loss, we used Cx3cr1-deficient *Cx3cr1*^GFP/GFP^ and WT *Cx3cr1*^GFP/+^ control mice. Micro-CT analysis revealed that after ovariectomy, Cx3cr1-deficient mice displayed moderate but significant higher BV/TV and trabecular number and lower trabecular separation than WT *Cx3cr1*^GFP/+^ mice ([Figure 1B--C](#fig1){ref-type="fig"}). They also had less TRAcP^+^ OCLs compared to OVX WT *Cx3cr1*^GFP/+^ mice ([Figure 1D](#fig1){ref-type="fig"}). Thus, Cx3cr1 deficiency partially protects against bone destruction in OVX mice.

![*Cx3cr1*-deficient mice display reduced bone loss after ovariectomy.\
(**A**) FACS analysis of Cx3cr1^+^ OCLs generated from BM cells from SHAM-operated and OVX WT mice. Histograms indicate the mean ± SD percentage of Cx3cr1^+^ i-OCLs (n = 4--5). (**B**) Representative images of femur µCT analysis from SHAM-operated and OVX WT *Cx3cr1*^GFP/+^ and Cx3cr1-deficient *Cx3cr1*^GFP/GFP^ mice 6 weeks post-surgery. (**C**) Histograms show the mean ± SD percentage of bone volume fraction (BV/TV), trabecular number and trabecular separation (n = 8 mice per group). (**D**) Representative TRAcP staining on femora from OVX Cx3cr1^GFP/+^ and Cx3cr1^GFP/GFP^ mice. Scale bar = 100 µm. (**E**) Ex vivo FACS analysis of CD11c^+^ DCs and (**F**) CD11b^+^Ly6C^hi^ MNs present in the BM of SHAM and OVX mice. Cells were gated as in [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"} and histograms are showing the absolute cell number of these populations in the bone marrow. \*\*p\<0.01; \*\*\*p\<0.001; n.s., no significant difference.](elife-54493-fig1){#fig1}

As Cx3cr1 is involved in the recruitment of OCL progenitors to the BM particularly under inflammatory conditions ([@bib10]), we examined i-OCL progenitors in the BM of OVX Cx3cr1-deficient *Cx3cr1*^GFP/GFP^ mice and WT *Cx3cr1*^GFP/+^ mice. While both DCs and Ly6C^hi^ MNs have been involved in the formation of OCLs in pathological conditions, only DCs were shown to give rise to Cx3cr1^+^ i-OCLs ([@bib20]). Thus, we analyzed the osteoclastogenic capacity of blood Ly6C^hi^ MNs sorted from *Cx3cr1*^GFP/+^ mice. About 35% of the resulting OCLs expressed GFP indicating that Ly6C^hi^ MNs are also progenitors of Cx3cr1^+^ OCLs ([Figure 1---figure supplement 1A--B](#fig1s1){ref-type="fig"}). FACS analysis in OVX mice revealed that both DCs and Ly6C^hi^ MNs increased in the BM of OVX *Cx3cr1*^GFP/+^ but not *Cx3cr1*^GFP/GFP^ mice ([Figure 1E--F](#fig1){ref-type="fig"}, [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). These results suggest that the reduced bone loss observed in Cx3cr1-deficient *Cx3cr1*^GFP/GFP^ mice is, at least partly, related to a decrease in BM progenitors of Cx3cr1^+^ OCLs, namely DCs and Ly6C^hi^ MNs.

Cx3cr1 deficiency does not alter immune and bone resorption function of Cx3cr1^+^ i-OCLs {#s2-2}
----------------------------------------------------------------------------------------

These results suggest a central role of Cx3cr1 in i-OCL differentiation. To further investigate underlying mechanisms, we performed the first comparative RNA-seq approach on GFP^+^ mature i-OCLs from WT *Cx3cr1*^GFP/+^ and Cx3cr1-deficient *Cx3cr1*^GFP/GFP^ mice ([Figure 2A](#fig2){ref-type="fig"}). OCLs represent a small population of cells firmly attached to the bone that cannot be isolated ex vivo in sufficient number for transcriptomic and functional assays ([@bib30]). Thus, i-OCLs were differentiated from BM-derived CD11c^+^ DCs of WT *Cx3cr1*^GFP/+^ and Cx3cr1-deficient *Cx3cr1*^GFP/GFP^ mice as described ([@bib20]). Mature Cx3cr1^+^ i-OCLs were then sorted based on their GFP expression and multinucleation according to [@bib30] ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).

![Cx3cr1 deficiency does not affect resorption and immune function in Cx3cr1^+^ i-OCLs.\
(**A**) Schematic representation of the differentiation of i-OCLs from BM-derived DCs of WT *Cx3cr1*^GFP/+^ and Cx3cr-deficient *Cx3cr1*^GFP/GFP^ mice. (**B**) RNA-seq analysis on sorted GFP^+^ i-OCLs (representing Cx3cr1^+^ i-OCLs) differentiated from BM-derived DCs of WT *Cx3cr1*^GFP/+^ and Cx3cr-1deficient *Cx3cr1*^GFP/GFP^ mice (gated as in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Volcano-plot indicates --Log~10~ adjusted p value versus log~2 ~fold-change comparing gene expression in i-OCL subsets. (**C**) Matrix dissolution activity of sorted GFP^+^ i-OCLs from WT *Cx3cr1*^GFP/+^ and Cx3cr1-deficient *Cx3cr1*^GFP/GFP^ mice seeded at the same cell density on a calcified matrix was evidence by red alizarin staining of the mineralized matrix. Unstained areas correspond to the resorbed areas. Left panel: representative images of resorbed area. Scale bar = 100 µm. Right panel: quantification of resorbed areas presented as mean ± SD percentage of three independent biological replicates each in triplicates. (**D**) FACS analysis of fluorescent-OVA uptake among GFP^+^ i-OCLs from *Cx3cr1*^GFP/+^ and *Cx3cr1*^GFP/GFP^ mice. Left panel: representative density plots and right panel: percentage of OVA^+^ cells from five independent experiments. (**E**) FACS analysis of GFP^+^ i-OCLs from *Cx3cr1*^GFP/+^ and *Cx3cr1*^GFP/GFP^ mice in at least four independent experiments. (**F**) T cell proliferation assay on CD4^+^ T cells labelled with CFSE and cultured in the presence of OVA-challenged GFP^+^ i-OCLs differentiated from *Cx3cr1*^GFP/+^ and *Cx3cr1*^GFP/GFP^ mice and analyzed by FACS after 4 days of coculture. (**G**) CD4^+^ T cells activated by OVA-challenged GFP^+^ i-OCLs from *Cx3cr1*^GFP/+^ and *Cx3cr1*^GFP/GFP^ mice were analyzed for their expression of TNFα and IFNγ by FACS after intracytoplasmic staining of these cytokines. n.s., no significant difference.](elife-54493-fig2){#fig2}

Except for their *Cx3cr1* expression, no differences were detected between GFP^+^ i-OCLs from Cx3cr1-deficient *Cx3cr1*^GFP/+^ and WT *Cx3cr1*^GFP/GFP^ mice suggesting that Cx3cr1 deficiency did not change the identity of i-OCLs ([Figure 2B](#fig2){ref-type="fig"}, [Figure 2---figure supplement 2A--B](#fig2s2){ref-type="fig"}). Similarly, functional in vitro assays revealed that regardless if they derived from Cx3cr1-deficient *Cx3cr1*^GFP/+^ or WT *Cx3cr1*^GFP/GFP^ mice, GFP^+^ i-OCLs had equivalent resorption activity, antigen-presentation capacity or expression of MHC-II and co-stimulatory molecules ([Figure 2C--E](#fig2){ref-type="fig"}). In addition, we performed a T cell activation assay using carboxyfluorescein succinimidyl ester (CFSE)-labelled CD4^+^ T cells from OT-II mice bearing a T cell receptor (TCR) specific for the immunodominant ovalbumin (OVA) peptide ([@bib5]). No differences between GFP^+^ i-OCLs from *Cx3cr1*^GFP/GFP^ versus *Cx3cr*1^GFP/+^ mice were found in their T cell activation and polarization capacity ([Figure 2F--G](#fig2){ref-type="fig"}). Thus, our results indicate that the function of the Cx3xr1 protein per se is not essential for the resorption and immune function of mature *Cx3cr1*-expressing i-OCLs.

Cx3cr1^+^ and Cx3cr1^neg^ i-OCLs are distinct populations {#s2-3}
---------------------------------------------------------

Although Cx3cr1 is important for i-OCL progenitors, its deficiency does not affect bone resorption or T cell activation by mature Cx3cr1-expressing i-OCLs. However, being expressed in part of i-OCLs, Cx3cr1 remains a marker for the heterogeneity of these i-OCLs. We explored this heterogeneity and in particular the specific role of Cx3cr1-expressing and Cx3cr1^neg^ i-OCL subsets, comparing them using an RNA-seq approach. Mature Cx3cr1^+^ and Cx3cr1^neg^ i-OCLs were generated in vitro from BM-derived CD11c^+^ DCs of WT *Cx3cr1*^GFP/+^ mice and sorted based on their GFP expression and multinucleation ([Figure 3A](#fig3){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}; [@bib30]). A total of 1771 genes were significantly differentially expressed (adj.pVal \<0.05, Log~2~FC ≥ 1) between the 2 populations. Principal Component Analysis (PCA) of all detectable genes revealed that Cx3cr1^+^ (GFP^+^) and Cx3cr1^neg^ (GFP^neg^) i-OCLs were clustered into 2 distinct populations ([Figure 3B](#fig3){ref-type="fig"}), which was reinforced by volcano plot and hierarchical clustering analysis of the top 107 significantly differently expressed genes (adj.pVal \<0.05 and Log~2~FC ≥ 1) ([Figure 3C--D](#fig3){ref-type="fig"}). In addition to *Cx3cr1*, genes interacting with its functional pathway were also differentially expressed ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). In particular, *Nr1d1*, a negative regulator of *Cx3cr1* ([@bib49]) was reduced whereas *Tlr4* that mediates *Cx3cr1* upregulation by LPS ([@bib39]) was increased in Cx3cr1^+^ versus Cx3cr1^neg^ i-OCLs ([Figure 3---figure supplement 1B--C](#fig3s1){ref-type="fig"}). These data suggest that *Cx3cr1* expression is tightly controlled during i-OCL differentiation. This was further confirmed by showing that Cx3cr1^+^ OCLs could be generated from either Cx3cr1^+^ or Cx3cr1^neg^ BM-derived DCs ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}). Thus, the expression of *Cx3cr1* in i-OCLs is not only inherited from their progenitors but may be acquired through a dynamic up-regulation during the differentiation of a subset of i-OCLs having a specific function. In particular, genes and functional pathways differentially expressed between Cx3cr1^+^ and Cx3cr1^neg^ i-OCLs ([Figure 3D--E](#fig3){ref-type="fig"}) strongly suggested that the function of Cx3cr1^+^ i-OCLs is related to the immune system. Therefore, we further characterized Cx3cr1^+^ and Cx3cr1^neg^ i-OCLs focusing on their bone resorption capacity and their immune potential.

![Transcriptomic profiling of Cx3cr1^+^ and Cx3cr1^neg^ i-OCLs reveals two distinct populations of i-OCLs.\
(**A**) Schematic representation of the differentiation of GFP^+^ (Cx3cr1^+^) and GFP^neg^ (Cx3cr1^neg^) i-OCLs from BM-derived DCs of WT *Cx3cr1*^GFP/+^ mice and their sorting (gated as in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). (**B**) Principal component analysis of Cx3cr1^+^ and Cx3cr1^neg^ i-OCLs clusters samples in two groups (red: GFP^+^ (Cx3cr1^+^) OCLs and blue GFP^neg^ (Cx3cr1^neg^) OCLs, both from *Cx3cr1*^GFP/+^ mice). Data shows the two first components on the top 500 most differentially expressed genes after batch correction. Each dot represents the expression profile of one sample. (**C**) Volcano-plot showing representative differentially expressed genes for Cx3cr1^+^ and Cx3cr1^neg^ i-OCLs. Cut-off values were defined by a fold change (FC) \>2 and an adjusted p-value\<0.05. (**D**) Heatmap visualization of the top 107 genes significantly differentially expressed between GFP^+^ (Cx3cr1^+^) and GFP^neg^ (Cx3cr1^neg^) i-OCLs from *Cx3cr1*^GFP/+^ mice (adjusted p-value\<0.05, FC ≥2). (**E**) Graphical representation of gene ontology analysis associated with differentially expressed genes between Cx3cr1^+^ and Cx3cr1^neg^ i-OCLs.](elife-54493-fig3){#fig3}

Transcriptomic profiling revealed that Cx3cr1^neg^ i-OCLs expressed higher levels of genes responsible for bone resorption ([Figure 4A](#fig4){ref-type="fig"}), which was confirmed by RT-qPCR ([Figure 4B](#fig4){ref-type="fig"}). We compared Cx3cr1^neg^ and Cx3cr1^+^ i-OCLs subsets to CD169^+^CD68^+^ macrophages that also express Cx3cr1 ([Figure 4---figure supplement 1A--B](#fig4s1){ref-type="fig"}). Our results revealed that both Cx3cr1^neg^ and Cx3cr1^+^ i-OCL subsets differed from BM-derived macrophages as they did not express CD68 and CD169 ([Figure 4---figure supplement 1C--D](#fig4s1){ref-type="fig"}). Moreover, the 2 i-OCLs subsets shared the main characteristics of OCLs, e.g. TRAcP expression and resorption activity ([Figure 4C--F](#fig4){ref-type="fig"}) while BM-macrophages did not express TRAcP ([Figure 4---figure supplement 1E](#fig4s1){ref-type="fig"}). However, when sorted mature Cx3cr1^neg^ and Cx3cr1^+^ i-OCLs were seeded at the same cell concentration, Cx3cr1^neg^ i-OCLs showed a higher matrix dissolution activity compared to Cx3cr1^+^ i-OCLs ([Figure 4E--F](#fig4){ref-type="fig"}). These results demonstrate that Cx3cr1^neg^ and Cx3cr1^+^ subsets correspond to 2 subsets of *bona fide* OCLs that differ in their resorption activity.

![Cx3cr1^neg^ and Cx3cr1^+^ i-OCLs differ in their resorbing activity.\
(**A**) Heatmap visualization of the z-scored expression for selected genes involved in bone resorption, osteoclast fusion and differentiation that are differentially expressed between GFP^+^ (Cx3cr1^+^) and GFP^neg^ (Cx3cr1^neg^) i-OCLs both differentiated from WT *Cx3cr1*^GFP/+^ mice (adjusted p-value\<0.05, FC ≥2). (**B**) RT-qPCR analysis on GFP^+^ (Cx3cr1^+^) and GFP^neg^ (Cx3cr1^neg^) i-OCLs. Results are represented as the mean with 95% confidence interval of 3 independent biological replicates in triplicates. (**C**) Flow cytometry analysis of TRAcP expression using ELF95 substrate in the 2 i-OCLs subsets. Percentage of positive cells (dark curve) compared to the negative control (light curve) is indicated. (**D**) Quantification of the mean fluorescence intensity (MFI) of TRAcP in GFP^+^ (Cx3cr1^+^) and GFP^neg^ (Cx3cr1^neg^) i-OCLs (n = 3). (**E**) Representative images of matrix dissolution activity of sorted GFP^+^ (Cx3cr1^+^) and GFP^neg^ (Cx3cr1^neg^) i-OCLs seeded at the same cell density. Red alizarin staining of the mineralized matrix revealed the resorbed areas as unstained. Scale bar = 100 µm. (**F**) Quantification of resorbed areas from three independent experiments in triplicates are indicated as percentage. \*\*\*\*p\<0.0001; n.s., no significant difference.](elife-54493-fig4){#fig4}

Besides these differences in bone resorption, RNA-seq data revealed significant differences in genes involved in antigen-processing and presentation ([Figure 5A](#fig5){ref-type="fig"}). Further in vitro analysis confirmed that whereas both i-OCL subsets engulfed OVA, this capacity was significantly decreased in Cx3cr1^neg^ i-OCLs ([Figure 5B--C](#fig5){ref-type="fig"}). In line with the RNA-seq data, FACS analysis confirmed that MHC-II molecules were more expressed in Cx3cr1^neg^ than Cx3cr1^pos^ i-OCLs ([Figure 5D](#fig5){ref-type="fig"}), while no significant differences were observed in the expression of CD80 and CD86 ([Figure 5E--F](#fig5){ref-type="fig"}). Moreover, Cx3cr1^neg^ i-OCLs showed higher capacity to induce T cell proliferation than Cx3cr1^+^ i-OCLs ([Figure 5G](#fig5){ref-type="fig"}). Nevertheless, both i-OCL subsets were able to induce TNFα and IFNγ-producing CD4^+^ T cells but not FoxP3^+^CD4^+^ regulatory T (Treg) cells ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), in accordance with the previously described immune properties of i-OCLs ([@bib20]).

![Cx3cr1^neg^ and Cx3cr1^+^ subsets differ in their antigen uptake and presentation.\
(**A**) Heatmap visualization of the z-scored expression for selected genes involved in antigen uptake, processing and presentation that are differentially expressed between GFP^+^ (Cx3cr1^+^) and GFP^neg^ (Cx3cr1^neg^) i-OCLs from WT *Cx3cr1*^GFP/+^ mice (adjusted pVal \<0.05, FC ≥2). (**B**) Representative FACS plots of OVA uptake in Cx3cr1^+^ and Cx3cr1^neg^ i-OCLs. (**C**) Quantification of FACS analysis for OVA uptake in GFP^+^ (Cx3cr1^+^) and GFP^neg^ (Cx3cr1^neg^) i-OCLs (n = 5). (**D--F**) FACS analysis of GFP^+^ (Cx3cr1^+^) and GFP^neg^ (Cx3cr1^neg^) i-OCLs for (**D**) MHC-II, (**E**) CD80 and (**F**) CD86 (n = 6). (**G**). Representative FACS histograms for T cell proliferation assay of CFSE-labelled CD4^+^ T cells from OT-II mice cultured with OVA-loaded GFP^+^ (Cx3cr1^+^) or GFP ^neg^ (Cx3cr1^neg^) i-OCLs after 5 days of coculture. \*\*p\<0.01; n.s., no significant difference.](elife-54493-fig5){#fig5}

Cx3cr1^+^ i-OCLs express immunosuppressive factors and control the immune function of Cx3cr1^neg^ i-OCLs in vitro {#s2-4}
-----------------------------------------------------------------------------------------------------------------

RNA-seq data also revealed that both i-OCLs subsets expressed inflammation-associated genes in line with their capacity to induce TNFα and IFNγ-producing CD4^+^ T cells ([Figure 6A](#fig6){ref-type="fig"}). However, Cx3cr1^+^ i-OCLs had significant higher expression of immunosuppressive genes ([Figure 6A](#fig6){ref-type="fig"}) that could contribute to their lower inflammatory potential. Further RT-qPCR of the immunosuppressive genes *CD274* (PD-L1), *Lgals9* (Galectin-9) and *Tnfrsf14* (HEVM) confirmed these findings ([Figure 6B](#fig6){ref-type="fig"}). Interestingly, blocking the PD-L1/PD-1 axis with an anti-PD-1 antibody in co-cultures of Cx3cr1^+^ i-OCLs and CD4^+^ T cells increased the capacity of Cx3cr1^+^ i-OCLs to induce T cell proliferation ([Figure 6C](#fig6){ref-type="fig"}). These findings reveal that PD-L1 plays a central role in the immunosuppressive potential of Cx3cr1^+^ i-OCLs. They also suggest that Cx3cr1^+^ i-OCLs could have an immunosuppressive effect on Cx3cr1^neg^ i-OCLs. Therefore, we set up an immunosuppressive assay where OVA-loaded Cx3cr1^neg^ i-OCLs were co-cultured with CFSE-labelled CD4^+^ T cells from OT-II mice. Different ratios of Cx3cr1^+^ i-OCLs not challenged with OVA (unable to directly activate OT-II T cells) were added to the culture ([Figure 6D](#fig6){ref-type="fig"}). Cx3cr1^neg^ i-OCLs alone (ratio 1:0) highly stimulated CD4^+^ T cell proliferation, which was dramatically decreased by the addition of Cx3cr1^+^ i-OCLs (ratio 1:2; [Figure 6E](#fig6){ref-type="fig"}). These data demonstrate that Cx3cr1^+^ i-OCLs are able to control the inflammatory activity of Cx3cr1^neg^ i-OCLs in vitro, suggesting the existence of a novel mechanism of interaction between OCLs in inflammatory conditions that remains to be addressed in vivo.

![Cx3cr1^neg^ and Cx3cr1^+^ subsets differ in their T cell activation capacity.\
(**A**) Heatmap visualization of the z-scored expression for selected genes involved in T cell stimulation and inhibition that are differentially expressed between GFP^+^ (Cx3cr1^+^) and GFP^neg^ (Cx3cr1^neg^) i-OCLs from WT *Cx3cr1*^GFP/+^ mice (adjusted p\<0.05, FC ≥2). (**B**) RT-qPCR analysis of immunosuppressive molecules. Graphs show three independent experiments conducted in triplicates. (**C**) Representative FACS histograms and quantification of the proliferation of CSFE-labelled CD4^+^ T cell from OT-II mice cocultured with OVA-loaded Cx3cr1^+^ i-OCLs from WT *Cx3cr1*^GFP/+^ mice and an isotype antibody (left panel) or an anti-PD-1 antibody (right panel). (**D**) Schematic representation of the experimental setup. Sorted GFP^neg^ (Cx3cr1^neg^) i-OCLs from WT *Cx3cr1*^GFP/+^ mice were loaded with OVA for 3 hr and incubated with CFSE^+^ CD4^+^ T cells in the presence of different rations of non-OVA loaded GFP^+^(Cx3cr1^+^) i-OCLs from WT *Cx3cr1*^GFP/+^ mice. (**E**) FACS analysis and quantification of CFSE^+^ CD4^+^ T cells of OT-II mice cocultured in the presence of different ratios (1:0; 1:1; 1:2) between OVA-loaded Cx3cr1^neg^ i-OCLs and Cx3cr1^+^ i-OCLs (non-loaded with OVA) for 5 days. \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001; \*\*\*\*p\<0.0001; n.s., no significant difference.](elife-54493-fig6){#fig6}

Discussion {#s3}
==========

This study provides further evidence of OCL heterogeneity. We previously demonstrated the existence of t-OCLs priming CD4^+^ Treg cells and i-OCLs inducing TNFα^+^CD4^+^ T cells that emerge under different conditions ([@bib20]). Here, we show that i-OCLs encompass two distinct populations of *bona fide* OCLs that can be distinguished by their *Cx3cr1* expression. Although these 2 i-OCL subsets prime TNFα-producing CD4^+^ T cells and resorb, they display different capacities for bone resorption and immunosuppression. Moreover, they do not activate Treg cells, and thus, they differ considerably from t-OCLs ([@bib20]). We also show that Cx3cr1^+^ i-OCLs control the inflammatory activity of Cx3cr1^neg^ i-OCLs in vitro, suggesting that different OCL subsets could interact with each other to control their immune activity, an hypothesis that remains to be investigated in vivo ([Figure 7](#fig7){ref-type="fig"}).

![Heterogeneity of osteoclasts and underlying molecular mechanisms.\
In steady state, BM progenitors differentiate into tolerogenic OCLs (t-OCLs) that are able to present antigens and induce CD4^+^ Treg cells. During inflammation, inflammatory MNs and DCs are recruited to the BM and differentiate into i-OCLs. Approx. 25% of these i-OCLs can be characterized by their expression of Cx3cr1 while the majority of i-OCLs does not express this marker. Cx3cr1^neg^ i-OCLs show significantly higher bone resorption activity in vitro compared to Cx3cr1^+^ i-OCLs. Both i-OCL subsets act as antigen-presenting cells but differ in their T cell activation capacity that is higher for the Cx3cr1^neg^ i-OCL subset. Both i-OCL subsets are able to induce TNFα-producing CD4^+^ T cells, however the Cx3cr1^+^ OCL subset express high levels of co-inhibitory molecules such as PD-L1 that reduce their capacity to activate T cells. Moreover, Cx3cr1^+^ i-OCLs have an immune suppressive effect on Cx3cr1 ^neg^ i-OCLs by reducing their T cell proliferation capacity in vitro.](elife-54493-fig7){#fig7}

Cx3cr1 is involved in the development and progression of chronic inflammatory diseases, such as colitis and arthritis ([@bib26]; [@bib45]; [@bib51]) while Cx3cr1 deficiency reduces the severity of these diseases ([@bib37]; [@bib45]; [@bib51]). Our results extend the protective effect of Cx3cr1 deficiency to OVX-induced bone destruction. As in inflammatory bowel disease, this model is driven by TNFα and RANK-L-producing CD4^+^ T cells leading to the development of Cx3cr1^+^ OCLs ([@bib9]; [@bib20]; [@bib57]). As a chemokine receptor, Cx3cr1 is required for the migration of monocytic cells and was suggested to participate in the maintenance of OCL progenitors particularly in inflammatory conditions ([@bib10]; [@bib17]; [@bib18]). Its ligand (Fractalkine/Cx3cl1) increases in OVX mice and osteoporotic patients and correlates with disease severity ([@bib11]; [@bib56]). Fractalkine-producing mesenchymal cells attract OCL precursors and support their differentiation ([@bib16]; [@bib35]). In agreement with these data, we demonstrate that the reduced bone loss in OVX Cx3cr1-deficient mice is related to a decrease in BM i-OCL precursors (DCs and Ly6C^hi^ MNs) and a reduced osteoclastogenesis. Although Cx3cr1-deficient mice were reported to have slightly reduced bone density ([@bib19]), we only observed moderate but significant differences in OVX mice, highlighting the importance of Cx3cr1 in pathological bone destruction. Compared to previous reports ([@bib19]), we gained advantage from working on purified mature i-OCLs from Cx3cr1-deficient mice and we did not observe any significant variations when comparing Cx3cr1^+^ i-OCLs from Cx3cr1-deficient *Cx3cr1*^GFP/GFP^ and WT *Cx3cr1*^GFP/+^ mice. Overall, our results demonstrate that the Cx3cr1/Cx3cl1 axis is essential for the increased BM recruitment and differentiation of i-OCL progenitors observed in OVX mice but that the Cx3cr1 protein *per se* is not involved in the resorption and immune function of fully mature i-OCLs.

This raises the question of the role of Cx3cr1 in a subset of mature i-OCLs. As OCLs permanently fuse with new monocytic cells ([@bib22]), Cx3cr1 could be considered as a marker for some of these progenitor cells that remains expressed in the resulting OCLs. However, Cx3cr1^+^ OCLs are induced by inflammatory cytokines such as IL-17 and TNFα and arise in conditions associated with inflammatory bone destruction ([@bib20]; [@bib31]). Furthermore, Cx3cr1^+^ and Cx3cr1^neg^ i-OCLs significantly differ in the expression of genes involved in Cx3cr1-interacting pathways. For instance, Cx3cr1^+^ OCLs show lower expression of *Nr1d1,* a Cx3cr1 inhibitor ([@bib49]) and higher levels of *Tlr4* that mediates the positive effects of LPS on Cx3cr1 ([@bib39]). Furthermore, we observed that Cx3cr1^+^ OCLs arise from both Cx3cr1^+^ and Cx3cr1^neg^ progenitors ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}), indicating that *Cx3cr1* expression by some mature OCLs is inducible and not solely inherited from their progenitors.

In line with our observations in OCLs, Cx3cr1 is also a marker for MN and DC diversity ([@bib15]; [@bib54]; [@bib59]). Depending on their environment, BM progenitors can differentiate into immunogenic Cx3cr1^low/neg^MHC-II^hi^ DCs or Cx3cr1^+^MHC-II^low^ macrophages with high antigen-uptake and a PD-L1-associated immunosuppressive function ([@bib61]). In the gut mucosa, Cx3cr1^hi^ macrophages efficiently take up antigens but induce lower T cell proliferation compared to CD103^+^Cx3cr1^neg^ DCs ([@bib47]). The balance between immunosuppressive Cx3cr1^hi^ and inflammatory Cx3cr1^low^ phagocytes in the gut is essential in controlling inflammatory responses in colitis ([@bib42]; [@bib58]). Accordingly, Cx3cr1^+^ and Cx3cr1^neg^ i-OCLs exert different immune functions. Cx3cr1^+^ cells were more efficient in antigen uptake but less potent in T cell activation than Cx3cr1^neg^ i-OCLs. In addition, as Cx3cr1^hi^ macrophages, Cx3cr1^+^ i-OCLs decrease T cell proliferation, notably via immunosuppressive molecules such as PD-L1, Galectin-9 and HVEM. These factors are major immune checkpoints involved in autoimmune disorders and tumor-induced immune suppression associated with T cell dysfunction, exhaustion, and low activation ([@bib6]; [@bib8]; [@bib14]; [@bib50]). Thus, their high expression in Cx3cr1^+^ i-OCLs further strengthens the hypothesis that Cx3cr1^+^ i-OCLs act as immunosuppressive cells emerging upon inflammatory signals to regulate inflammation, which was confirmed in vitro by a functional immunosuppressive assay ([Figure 6](#fig6){ref-type="fig"}).

The contribution of OCLs to an immunosuppressive BM microenvironment has been recently explored in the context of multiple myeloma (MM). Bone destruction in MM is supported by malignant plasma cells that favor OCL differentiation, including from DCs, through high RANK-L, IL-17 and TNFα production ([@bib34]; [@bib38]; [@bib53]). In these conditions, OCLs suppress T cell activation via PD-L1, Galectin-9 and HVEM ([@bib2]; [@bib34]; [@bib50]). Although OCL heterogeneity was not investigated in MM, osteoclastogenic conditions are similar to those supporting the differentiation of Cx3cr1^+^ i-OCLs ([@bib20]). Thus, our results provide new insights into the immunosuppressive property of OCLs and suggest that Cx3cr1^+^ i-OCLs are likely to be involved in pathological conditions such as MM.

Although Cx3cr1^+^ and Cx3cr1^neg^ i-OCLs both induce TNFα-producing CD4^+^ T cells and are resorbing cells, we showed that mature Cx3cr1^neg^ i-OCLs are more efficient to induce CD4^+^ T cell proliferation and have a higher resorption capacity in vitro than Cx3cr1^+^ i-OCLs. This suggests that Cx3cr1^neg^ i-OCLs play a major role in inflammatory bone destruction such as in osteoporosis and chronic inflammatory diseases. Interestingly, when comparing Cx3cr1^+^ i-OCLs from Cx3cr1-deficient *Cx3cr1*^GFP/GFP^ and WT *Cx3cr1*^GFP/+^ mice no differences were observed. Thus, the Cx3cr1 protein as such is not essential for the immunomodulatory and bone resorbing function of Cx3cr1^+^ i-OCLs. However, it remains a membrane marker allowing to distinguish between 2 i-OCLs subsets (namely Cx3cr1^+^ and Cx3cr1^neg^ i-OCLs) exerting different immunomodulatory roles. Apart from the lack of Cx3cr1 expression and their immunogenic effect, there is currently no specific marker for the identification of Cx3cr1^neg^ i-OCLs. Thus, an in-depth characterization of these cells is necessary to fully address their specific role. Interestingly, Cx3cr1^neg^ i-OCLs induce high proportions of TNFα and IFNγ-producing CD4^+^ T cells in vitro. These cytokines are potent inducers of Cx3cr1 and PD-L1 ([@bib6]; [@bib36]; [@bib52]) suggesting that TNFα-producing T cells induced by Cx3cr1^neg^ i-OCLs may participate in the regulation of Cx3cr1^+^ i-OCLs. This observation supports the existence of a regulatory loop between pro-inflammatory Cx3cr1^neg^ i-OCLs and immunosuppressive Cx3cr1^+^ i-OCLs that negatively regulate Th1 cell activation to control inflammation and that remains to be confirmed in vivo. Therefore, our findings suggest that the balance between the 2 i-OCL subsets would be an important aspect of the immune regulation during inflammatory bone loss.

In summary, we describe 2 OCL subsets that arise during inflammation and that are characterized by their *Cx3cr1* expression ([Figure 7](#fig7){ref-type="fig"}). While Cx3cr1^neg^ i-OCLs mediate inflammatory bone destruction, Cx3cr1^+^ i-OCLs are more prone to immunosuppression. This might contribute to the regulation of inflammatory processes but also to maintain an immunosuppressive BM microenvironment. Therefore, our in vitro data suggest the existence of a negative feedback mechanism by a gatekeeper subset of *Cx3cr1*-expressing i-OCLs during inflammation. This strongly emphasizes the heterogeneity of i-OCLs and provides new insights in their inflammatory function. Our study uncovered a hitherto neglected OCL diversity that contributes to a deeper understanding of the balance between inflammation and immunosuppression in the BM. Interestingly, OCL-related reduction of T cell activation can be restored using anti-PD-1 antibodies. Thus Cx3cr1^+^ i-OCLs might represent a novel promising target to overcome the OCL-mediated immunosuppression and restore an anti-tumorigenic BM microenvironment. On the other hand, our results suggest that Cx3cr1^neg^ i-OCLs are promising targets against inflammatory bone destruction. A deeper comprehension of OCL diversity is therefore indispensable to identify more specific markers and to evaluate the therapeutic interest of targeting specific OCL subsets.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                Designation                                   Source or\                Identifiers       Additional\
  (species) or\                                                                              reference                                   information
  resource                                                                                                                               
  -------------------------------------------- --------------------------------------------- ------------------------- ----------------- ---------------------------------------------------
  Strain, strain background (*Mus musculus*)   Cx3cr1^GFP/+^                                 [@bib23]                                    CDTA, CNRS, Orléans, France

  Sequenced-based reagent                      *Calcr*                                                                 PCR primers       CTTCCATGCTGATCTTCTGG andCAGATCTCCATTGGGCACAA

  Sequenced-based reagent                      *Acp5*                                                                  PCR primers       TGCCTACCTGTGTGGACATGA andCACATAGCCCACACCGTTCTC

  Sequenced-based reagent                      *Mmp9*                                                                  PCR primers       TGAGTCCGGCAGACAATCCT and CGCCCTGGATCTCAGCAATA

  Sequenced-based reagent                      *Ctsk*                                                                  PCR primers       CAGCAGAGGTGTGTACTATG and GCGTTGTTCTTATTCCGAGC

  Sequenced-based reagent                      *Atp6V0a3*/*Tcirg1*                                                     PCR primers       CGCTGCGAGGAACTGGAG and AGCGTCAGACCTGCCCG

  Sequenced-based reagent                      *Tnfrsf11a*                                                             PCR primers       CTTGGACACCTGGAATGAAGAAG and AGGGCCTTGCCTGCATC

  Sequenced-based reagent                      *Nfatc1*                                                                PCR primers       TGAGGCTGGTCTTCCGAGTT and CGCTGGGAACACTCGATAGG

  Sequenced-based reagent                      *Dcstamp*                                                               PCR primers       GGGCACCAGTATTTTCCTGA and CAGAACGGCCAGAAGAATGA

  Sequenced-based reagent                      *Oscar*                                                                 PCR primers       GTAACGGATCAGCTCCCCAG and CGCGGTACAGTGCAAAACTC

  Sequenced-based reagent                      *CD274*                                                                 PCR primers       CAAGCGAATCACGCTGAAAG and GGGTTGGTGGTCACTGTTTGT

  Sequenced-based reagent                      *Lgals9*                                                                PCR primers       TCAAGGTGATGGTGAACAAGAAA and GATGGTGTCCACGAGGTGGTA

  Sequenced-based reagent                      *Lightr/Tnfrsf14*                                                       PCR primers       TGTCCATTCTTTTGCCACTTG and CCTGATGGTGTTCTCCTGTTGTT

  Sequenced-based reagent                      *36B4*                                                                  PCR primers       TCCAGGCTTTGGGCATCA and CTTTATCAGCTGCACATCACTCAGA

  Antibody                                     Monoclonal anti-mouse CD80                    BD Biosciences            clone 16-10A1     APC-conjugated\
                                                                                                                                         (1:100)

  Antibody                                     Monoclonal anti-mouse CD86                    BD Biosciences            clone GL1         PE-conjugated\
                                                                                                                                         (1:100)

  Antibody                                     Monoclonal anti-mouse I-A\[b\]                BD Biosciences            clone AF6-120.1   Biotin-conjugated\
                                                                                                                                         (1:200)

  Antibody                                     Monoclonal anti-mouse/human CD11b             BD Biosciences            clone M1/70       PE-conjugated\
                                                                                                                                         (1:500)

  Antibody                                     Monoclonal anti-mouse CD4                     BD Biosciences            clone RM4-5       PECy7-conjugated\
                                                                                                                                         (1:1000)

  Antibody                                     Monoclonal anti-mouse CD68                    ThermoFisher Scientific   clone FA-11       PECy7-conjugated\
                                                                                                                                         (1:200)

  Antibody                                     Monoclonal anti-mouse CD11c                   ThermoFisher Scientific   clone N418        PECy7-conjugated\
                                                                                                                                         (1:200)

  Antibody                                     Monoclonal anti-mouse Ly6C                    ThermoFisher Scientific   clone HK1.4       PerCP-conjugated\
                                                                                                                                         (1:1000)

  Antibody                                     Monoclonal anti-mouse CD169                   ThermoFisher Scientific   clone SER-4       APC-conjugated\
                                                                                                                                         (1:100)

  Antibody                                     Monoclonal anti-mouse IFNγ                    ThermoFisher Scientific   clone XMG1.2      APC-conjugated\
                                                                                                                                         (1:400)

  Antibody                                     Monoclonal anti-mouse TNFα                    ThermoFisher Scientific   clone MP6-XT22    BV421-conjugated\
                                                                                                                                         (1:400)

  Chemical compound, drug                      streptavidin                                  ThermoFisher Scientific                     PercP-conjugated\
                                                                                                                                         (1:200)

  Chemical compound, drug                      ovalbumin                                     ThermoFisher Scientific                     Alexa Fluor 647-conjugated

  Commercial assay or kit                      Acid Phosphatase Leucocyte (TRAcP) kit        Sigma-Aldrich             387A              

  Commercial assay or kit                      ELF 97 Endogenous Phosphatase Detection Kit   Molecular probes          E-6601            
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice and ovariectomy-induced osteoporosis {#s4-1}
-----------------------------------------

OT-II mice were purchased from Charles River Laboratory and C57BL/6 *Cx3cr1*^GFP/+^ mice were kindly provided by F. Laurent (INRA, Nouzilly, France). Animals were maintained under a 12 hr light/12 hr dark cycle with free access to water and standard mouse diet. For ovariectomy, female mice were randomly divided into 2 groups, which were then sham-operated (SHAM) or ovariectomized (OVX). Ovariectomy and sham surgery were performed on 6 weeks old *Cx3cr1*^GFP/+^ and *Cx3cr1*^GFP/GFP^ female mice after anesthesia with isoflurane. The animals were intensively monitored for 72 hr after the procedure. Animals were weighed at the beginning of the study and twice a week thereafter. Six weeks after ovariectomy, mice were sacrificed. Uteri were weighed to control the quality of ovariectomy (not shown). Bones were used either for bone marrow cell isolation and further flow cytometry analysis or for subsequent µCT and histological analysis. Approval for animal experiments was obtained from the Institutional Ethics Committee on Laboratory Animals (CIEPAL-Azur, Nice Sophia-Antipolis, France) and experiments were conducted in compliance with ethical regulations for animal testing and research.

Bone analyses {#s4-2}
-------------

Femora were fixed in 4% paraformaldehyde (PFA) overnight. Subsequently, microcomputed tomography (µCT) was performed using the Skyscan 1176 µCT system (Bruker µCT, Belgium) at the preclinical platform ECELLFRANCE (IRMB, Montpellier, France). Scans were performed using isotropic voxels size of 18 µm, voltage of 50 kV, current of 500 mA, 0.5 mm aluminum filter, 180 degrees with a 0.7-degree rotation step and 210 ms exposure time. Data 3D reconstructions were generated for visual representation using NRecon software (Bruker µCT, Belgium).

For histological analysis, fixed femora were decalcified in 10% EDTA for 10 days, embedded in paraffin and tartrate-resistant acid phosphatase (TRAcP) staining was performed on 7 µm sections following manufacturer's recommendations (Sigma).

Primary osteoclast culture {#s4-3}
--------------------------

As OCLs cannot be isolated directly ex vivo in sufficient number for subsequent functional analysis, inflammatory OCLs (i-OCLs) were differentiated in vitro from BM-derived CD11c^+^ DCs or from blood CD11b^+^ Ly6C^hi^ MNs of 6 week old WT *Cx3cr1*^GFP/+^ and deficient *Cx3cr1*^GFP/GFP^ mice as previously described ([@bib20]). Briefly, bone marrow was flushed out of the long bones and after red blood cell lysis, BM cells were cultured in 24-well plates at 0.5 × 10^6^ cells/well in RPMI medium (ThermoFisher Scientific) supplemented with 5% serum (Hyclone, GE Healthcare), 1% penicillin-streptomycin, 50 µM β-mercaptoethanol (both from ThermoFisher Scientific), 10 ng/ml IL-4 and 10 ng/ml GM-CSF (both from PeproTech). CD11c^+^ DCs were sorted using anti-CD11c antibody (1:200; HL3; BD Biosciences) and anti-biotin microbeads (Miltenyi Biotec). Alternatively, when indicated, i-OCLs were obtained from blood SSC^lo^ CD11b^+^ Ly6C^hi^ MNs of *Cx3cr1*^GFP/+^ OVX mice sorted on a FACS-Aria II (BD Biosciences) using anti-CD11b and Ly6C antibodies. For i-OCLs culture, 2 × 10^4^ CD11c^+^ DCs or CD11b^+^ Ly6C^hi^ MNs were seeded/well on 24-well plates in MEM-alpha (ThermoFisher Scientific) supplemented with 5% serum (Hyclone, GE Healthcare), 1% penicillin-streptomycin, 50 µM β-mercaptoethanol, 25 ng/ml M-CSF and 30 ng/ml RANK-L (both R and D). Cells were cultured at 37°C and 5% CO~2~. Medium was changed every 3--4 days. Fully differentiated i-OCLs were stained with TRAcP (Sigma-Aldrich) according to manufacturer's instructions or collected from the culture plates using Accutase (Sigma-Aldrich) and used for subsequent FACS analysis or FACS sorting based on their nuclei number using H33342 (Sigma-Aldrich) as described previously ([@bib30]). When indicated, macrophages were differentiated in vitro from total BM cells (0.5 × 10^6^ BM cells/well in 24-well plates) in MEM-alpha supplemented with 5% serum (Hyclone, GE Healthcare), 1% penicillin-streptomycin, 50 µM β-mercaptoethanol and 25 ng/ml M-CSF for a total of 6 days.

FACS and cell sorting on osteoclasts {#s4-4}
------------------------------------

Mature in vitro differentiated i-OCLs were analyzed and sorted based on their multinucleation and GFP expression as described previously ([@bib30]) using flow cytometry analysis. Briefly, cells were incubated with 5 µg/ml H33342 (Sigma-Aldrich) in PBS 1X supplemented with 1% FBS and 2 mM EDTA (PSE) for 30 min at 37°C. For cell sorting, cells were filtered through a 100 µm nylon mesh and sorted on a FACS Aria IIu (BD Bioscience) using a 100 µm nozzle at a flow rate of 2000 events/s. Sorted cells were collected in FBS. Hoechst-stained i-OCLs from *Cx3cr1*^GFP^ mutant mice were labeled with antibodies specific for murine anti-CD80, CD86 and IAb (MHC-II, biotinylated) antibodies with a PercP-conjugated streptavidin in PSE for 15 min on ice. For antigen-uptake, mature OCLs were collected and incubated in the presence of 25 µg/ml ovalbumin (ThermoFisher Scientific) for 2.5 hr at 37°C before adding 5 µg/ml H33342 staining for another 30 min and subsequent FACS acquisition. Gating strategies for Cx3cr1^+^ and Cx3cr1^neg^ i-OCLs are shown in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}. For FACS analysis of TRAcP expression, OCLs were stained using the ELF97 substrate according to the manufacturer\'s protocol (endogenous phosphatase detection kit; Molecular Probes).

For ex vivo FACS analysis of OCL progenitors, after red blood cell lysis (Sigma-Aldrich) BM cells were labelled with anti-CD11c, CD11b and Ly6C antibodies. For FACS analysis of macrophages, BM-derived macrophages were labeled with anti-CD68 and CD169 antibodies.

For intracellular cytokine analysis, CD4^+^ T cells were stimulated with PMA, ionomycin and Brefeldin A, labelled with an anti-CD4 antibody and fixed with 4% formaldehyde overnight as described ([@bib12]). Cells were stained with anti-IFNγ and TNFα antibodies in Saponin 1X. Data were acquired using a FACS Canto-II (BD Biosciences).

Resorption assay {#s4-5}
----------------

Mature in vitro differentiated i-OCLs were sorted based on their multinucleation and GFP (Cx3cr1) expression as described above ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}; [@bib30]). A total of 10^3^ Cx3cr1^+^ or Cx3cr1^neg^ i-OCLs was seeded/well on a 96-well osteoassay plate (Corning) in MEM-alpha containing 10% FBS (Hyclone, GE Healthcare) and 30 ng/ml RANK-L (R and D). After 48 hr, matrix dissolution activity was evaluated by removing the cells using distilled sterile water and staining with 2% Alizarin Red (Sigma-Aldrich) for 1 min. Imaging was performed using an Axio Observer D1 microscope (Zeiss) and images were taken using AxioVision Rel. 4.8 software (Zeiss). Resorbed areas were quantified using Fiji/ImageJ software ([@bib46]).

T cell proliferation and immune suppression assay {#s4-6}
-------------------------------------------------

Mature in vitro differentiated Cx3cr1^+^ and Cx3cr1^neg^ i-OCLs were sorted based on their multinucleation and GFP expression as mentioned above ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) and seeded on 96-well plates with 10^3^ cells/well in the presence of 600 nM ovalbumin (OVA) peptide (ThermoFisher Scientific). Spleens of 8 weeks old OT-II mice were used to isolate CD4^+^ T cells that express transgenic OVA-specific αβ-TCRs by using the Dynabeads Untouched Mouse CD4 Cell Isolation Kit (ThermoFisher Scientific) according to manufacturer's specifications. To analyze T cell proliferation, CD4^+^ T cells were labelled with 250 µM CFSE for 10 min at 37°C. OVA-loaded i-OCLs and CD4^+^ T cells were seeded in a ratio 1:20 in IMDM medium supplemented with 5% FCS (Hyclone, GE Healthcare), 1% penicillin-streptomycin (Gibco) and 50 µM β-mercaptoethanol (Gibco). T cell proliferation was assessed by FACS after 3--5 days.

Implication of the PD-1/PD-L1 axis was evaluated by adding 5 µg/ml isotype control or anti-PD-1 (clone Rpm 14--1; kindly provided by V. Vouret (IRCAN, Nice, France)) antibodies at the beginning to the coculture. To validate the immune suppressive effect of Cx3cr1^+^ i-OCLs, sorted Cx3cr1^neg^ i-OCLs were stimulated with 600 nM OVA for 3 hr at 37°C, washed 3 times with IMDM medium and cultured together with CFSE-labelled CD4^+^ T cells from transgenic OT-II mice on 96-well plates as described above. Cx3cr1^+^ i-OCLs were sorted and added to the coculture without ovalbumin challenge in different ratios between Cx3cr1^neg^ vs Cx3cr1^+^ i-OCLs (1:1; 1:2; 2:1). T cell proliferation was assessed using FACS after 3--5 days of coculture.

RNA sequencing on sorted osteoclasts {#s4-7}
------------------------------------

Total RNA (100 ng) from 4 biological replicates (from 4 different mice) in each group was extracted from in vitro differentiated i-OCLs (after sorting according to their multinucleation and GFP expression as described above and shown in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) with the RNeasy kit (Qiagen) and processed for directional library preparation using the Truseq stranded total RNA library kit (Illumina). Libraries were pooled and sequenced paired-ended for 2 × 75 cycles on a Nextseq500 sequencer (Illumina) to generate 30--40 million fragments per sample. After quality controls, data analysis was performed with 2 different approaches. For the first one, reads were 'quasi' mapped on the reference mouse transcriptome (Gencode vM15) and quantified using the SALMON software with the mapping mode and standard settings ([@bib40]). Estimates of transcripts counts and their confidence intervals were computed using 1000 bootstraps to assess technical variance. Gene expression levels were computed by aggregating the transcript counts for each gene. Gene expression in biological replicates (n = 4) was then compared using a linear model as implemented in Sleuth ([@bib41]) and a false discovery rate of 0.01. Lists of differentially expressed genes were annotated using Innate-DB and EnrichR web portals. For the second approach, raw RNAseq fastq reads were trimmed with Trimmomatic and aligned to the reference mouse transcriptome (Gencode mm10) using STAR (v. 2.6.1 c) ([@bib13]) on the National Institutes of Health high-performance computing Biowulf cluster. Gene-assignment and estimates counts of RNA reads were performed with HTseq ([@bib3]). Further analyses were performed with R software and gene expression in biological replicates (n = 4) was compared between the different conditions to identify differentially expressed genes using DESeq2 ([@bib29]) with the Wald test (FDR \< 0.01). Batch removal was performed using limma ([@bib43]). Gene ontology (GO) pathway analyzes were performed using Goseq ([@bib60]). Both approaches gave equivalent results (not shown).

Gene expression analyses {#s4-8}
------------------------

Total RNA of sorted in vitro differentiated Cx3cr1^+^ and Cx3cr1^neg^ i-OCLs was extracted using TRIzol reagent with subsequent isopropanol precipitation following manufacturer's instructions. RT-qPCR was performed after reverse transcription (Superscript II, Life Technologies) as described previously ([@bib33]) using SYBR Green and the primers indicated in the Key ressources table. Samples of 3 biological replicates were run in triplicates and results were normalized to the reference gene *36B4* using the 2^−ΔCt^ method as described ([@bib32]).

Statistical analyses {#s4-9}
--------------------

All data were analyzed using Graph Pad Prism 7.0 software using an appropriate two tailed student's *t*-test with Bonferroni adjustment when comparing two groups. When more than two groups were compared two-way analysis of variance (ANOVA) was used. Statistical significance was considered at p\<0.05. Experimental values are presented as mean ± standard deviation (SD) of at least three biological replicas. Error bars for gene expression analysis of humans and mice using RT-qPCR show the mean value with 95% confidence interval. All experiments were repeated with a minimum of three biological replicates and at least two technical replicates.
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###### Raw counts-HTSeq.

Raw counts (HTseq) per gene and per sample from the RNAseq analysis of Cx3cr1^+^ and Cx3cr1^neg^ i-OCLs from WT *Cx3cr1*^GFP/+^ mice and Cx3cr1^+^ i-OCLs from deficient *Cx3cr1*^GFP/GFP^ mice. In each group, the 4 i-OCL samples have been obtained from 4 different mice.

###### Counts_Deseq NormaBatch Corrected.

Counts per gene and per sample after normalization and batch correction from the RNAseq analysis of Cx3cr1^+^ and Cx3cr1^neg^ i-OCLs from WT *Cx3cr1*^GFP/+^ mice and Cx3cr1^+^ i-OCLs from deficient *Cx3cr1*^GFP/GFP^ mice. In each group, the 4 i-OCL samples have been obtained from 4 different mice.

###### Cx3cr1^+^ i-OCLs from WT *Cx3cr1*^GFP/+^ mice versus Cx3cr1^+^ i-OCLs from deficient *Cx3cr1*^GFP/GFP^ mice \_Deseq.

Statistics (Deseq) for the comparison of expressed genes in Cx3cr1^+^ i-OCLs from WT *Cx3cr1*^GFP/+^ mice versus Cx3cr1^+^ i-OCLs from deficient *Cx3cr1*^GFP/GFP^ mice. In each group, the 4 i-OCL samples have been obtained from 4 different mice.

###### Cx3cr1^+^ i-OCLs from WT *Cx3cr1*^GFP/+^ mice versus Cx3cr1^neg^ i-OCLs from WT *Cx3cr1*^GFP/+^ mice mice \_Deseq.

Statistics (Deseq) for the comparison of expressed genes in Cx3cr1^+^ versus Cx3cr1^neg^ i-OCLs from WT *Cx3cr1*^GFP/+^ mice. In each group, the 4 i-OCL samples have been obtained from 4 different mice.
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Essential revisions:

1\) The conclusions rely on (1) gene expression profiling of sorted CX3CR1+ and CX3CR1- cells, and (2) in vitro culture followed by functional analysis of said sorted cells. However, for these in vitro experiments, the culture conditions employed prior to analysis are not clear. The Materials and methods section suggests that there was extensive culture and stimulation prior to analysis following sorting, but these conditions are not explicitly stated in the main text. If cells were extensively cultured with stimulating cytokines prior to functional analysis, then this would be expected to drastically change their functional profile compared to cells sorted directly from the in vivo environment. This would affect the results in Figures 2, 4, 5, and 6.

2\) While Cx3cr1+ and Cx3cr1- cells have different effects on T cell proliferation, that doesn\'t necessarily mean that one regulates the activity of the other in vivo. To make this conclusion it would be necessary to deplete selectively one population in vivo and observe the effects on the other population.

3\) Given that macrophages can fuse into multinucleated cells and that Cx3cr1 is a marker of macrophage heterogeneity, it has not been demonstrated that the cells were indeed OCLs and not macrophages. Evidence of the cell identity, OCL or macrophage should be provided.

4\) The absence of Cx3cr1 in Cx3cr1 gfp/gfp mice resulted in reduced recruitment of dendritic cells and Ly6C-hi monocytes to the sites of bone resorption in OVX animals. This result would be expected because Cx3cr1 is well known to be involved in leukocyte trafficking. The authors concluded that this result shows that Ly6C-hi monocytes are progenitors of inflammatory OCLs. This conclusion is not supported by the results.

5\) The authors conclude that Cx3cr1+ cells express higher levels of immunosuppressive genes compared to Cx3cr1- cells. Because the list of genes clearly includes many genes that are immunostimulatory (IL1b, CCL5, Nfkb1, Ccl2, Cd80, CD86), the conclusions about immunosuppressive gene expression profile in Cx3cr1- cells are not clearly supported.

6\) In Figure 1 the authors claim that CXC3R1 positive osteoclasts are needed for the full bone resorbing activity of osteoclasts after ovariectomy. The claim is based on only minor differences and whether CXC3R1 positive osteoclasts were preset or not, the osteoporosis phenotype develops in an equally severe manner. Moreover, these data contradict a statement made later in the paper that CXC3R1 positive osteoclasts are not needed for bone resorption.

7\) Data shown in Figure 2 (no difference in the bone resorption capacities of CX3CR1+ cells isolated from GFP/+ mice and CX3CR1- cells isolated from GFP/GFP mice) and those shown in Figure 4 (large differences in bone resorptive capacities of CX3CR1+ and CX3CR1-negative cells derived from dendricytes) are contradictory. This inconsistency calls into question the validity of using cells derived from the dendricytes in culture if they behave differently from the mature cells isolated from the genetically modified mice.
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Author response

> Essential revisions:
>
> 1\) The conclusions rely on (1) gene expression profiling of sorted CX3CR1+ and CX3CR1- cells, and (2) in vitro culture followed by functional analysis of said sorted cells. However, for these in vitro experiments, the culture conditions employed prior to analysis are not clear. The Materials and methods section suggests that there was extensive culture and stimulation prior to analysis following sorting, but these conditions are not explicitly stated in the main text. If cells were extensively cultured with stimulating cytokines prior to functional analysis, then this would be expected to drastically change their functional profile compared to cells sorted directly from the in vivo environment. This would affect the results in Figures 2, 4, 5, and 6.

The reviewers raised an important point. We generated in vitro inflammatory OCLs in the presence of RANK-L and M-CSF, the 2 main osteoclastogenic factors, according to the gold standard protocol for in vitro osteoclastogenesis and starting from their known progenitors, BM-derived dendritic cells (Ibanez et al., 2016). Of course, we agree that investigating osteoclast function on *ex-vivo* isolated osteoclasts would have been the best approach. However, up to now, there are no publications investigating osteoclast function on murine ex vivo-isolated osteoclasts. These cells are rare and firmly attached to the bone and to date there\'s no procedure in the literature to isolate them in sufficient number to perform subsequent analysis. Consequently, functional assays on osteoclasts always use in vitro-generated cells and much of osteoclast biology described so far in the literature has been investigated in such conditions (Madel et al., 2018). Moreover, at the moment there is no marker to distinguish between inflammatory and tolerogenic Cx3cr1^neg^ osteoclasts, which make it impossible to sort them ex vivo. Up to know, the only way to obtain these cells is to differentiate them from their respective known progenitors. Of course, we agree with the reviewers that this may affect their function, but to the same extend as in all studies investigating osteoclast activity and published so far and we don\'t have any other option.

To make the procedure of osteoclast preparation clearer as requested, we revised the main text and included more details in the Results and Materials and methods sections as well as in the figure legends. We also added in Figure 2 and Figure 3 a schematic representation of osteoclast preparation.

> 2\) While Cx3cr1+ and Cx3cr1- cells have different effects on T cell proliferation, that doesn\'t necessarily mean that one regulates the activity of the other in vivo. To make this conclusion it would be necessary to deplete selectively one population in vivo and observe the effects on the other population.

The reviewers are perfectly right and demonstrating the interaction between the 2 i-OCLs subsets in vivo would require specific depletion in vivo of one of these subsets. We are currently investigating in more details the heterogeneity of the different OCL subsets in order to identify suitable factors that would allow to specifically target one or the other OCL subset. This study, and in particular the validation of markers, requires time and the data will be published in a future manuscript.

However, to address the reviewer\'s concern and to avoid any over-interpretation of our results, in the revised manuscript we softened our conclusion and clearly stated that the mechanisms we described are only shown in vitro and remain to be demonstrated in vivo.

> 3\) Given that macrophages can fuse into multinucleated cells and that Cx3cr1 is a marker of macrophage heterogeneity, it has not been demonstrated that the cells were indeed OCLs and not macrophages. Evidence of the cell identity, OCL or macrophage should be provided.

To prove the identity of the cells we are analyzing, we performed additional experiments as requested. In particular, because in our protocol osteoclasts are generated in the presence of RANK-L but also M-CSF, a potent inducer of macrophages, we compared these osteoclasts to macrophages generated from bone marrow cells in the presence of M-CSF. In these conditions, we didn\'t observed cell fusion in macrophages. Moreover, our results showed that while BM-derived macrophages express the 2 BM macrophage markers CD68 and CD169 but are negative for TRAcP expression (Figure 4---figure supplement 1), both Cx3cr1^+^ and Cx3cr1^neg^ subsets of OCLs do not express these macrophage markers but share osteoclast hallmarks, such as TRAcP expression and resorption capacity (Figure 4C-F). These data were included in the revised manuscript and confirm that the cells we are analyzing are *bona fide* OCLs, whether they express or not Cx3cr1.

> 4\) The absence of Cx3cr1 in Cx3cr1 gfp/gfp mice resulted in reduced recruitment of dendritic cells and Ly6C-hi monocytes to the sites of bone resorption in OVX animals. This result would be expected because Cx3cr1 is well known to be involved in leukocyte trafficking. The authors concluded that this result shows that Ly6C-hi monocytes are progenitors of inflammatory OCLs. This conclusion is not supported by the results.

Ly6C^hi^ monocytes are involved in osteoclastogenesis in particular in conditions related to inflammatory bone destruction (Seeling et al., 2013; Ammari et al., 2018; Madel et al., 2019), which suggest that they could be progenitors of Cx3cr1^+^ osteoclasts that are also associated to the same conditions (Ibanez et al., 2016). To address the capacity of Ly6C^hi^ monocytes to differentiate into Cx3cr1^+^ osteoclasts, we sorted Ly6C^hi^ monocytes from the blood of WT *Cx3cr1*^GFP/+^ mice and cultured them with M-CSF and RANKL for 6 days as shown in Figure 1---figure supplement 1A. We analyzed the resulting osteoclasts by FACS and found that about 35% of these osteoclasts are GFP/Cx3cr1^+^ (Figure 1---figure supplement 1B) demonstrating that Ly6C^hi^ monocytes are indeed progenitors of Cx3cr1^+^ osteoclasts, which support our conclusion. To make this point more visible and clearer in the revised version of the manuscript, we modified the text in the Results section and added a schematic representation of the experiment (Figure 1---figure supplement 1A).

> 5\) The authors conclude that Cx3cr1+ cells express higher levels of immunosuppressive genes compared to Cx3cr1- cells. Because the list of genes clearly includes many genes that are immunostimulatory (IL1b, CCL5, Nfkb1, Ccl2, Cd80, CD86), the conclusions about immunosuppressive gene expression profile in Cx3cr1- cells are not clearly supported.

There might be a typo error (Cx3cr1- instead of Cx3cr1+) in the last sentence of the reviewer\'s comment because we only discussed the immunosuppressive capacity of Cx3cr1^+^ cells, not of Cx3cr1^neg^ cells.

The reviewers are perfectly right and Cx3cr1^+^ osteoclasts do not only express high levels of immunosuppressive genes but also of genes involved in inflammation (Figure 6A), which is in line with their capacity to stimulate to some extend the proliferation of inflammatory CD4^+^ T cell (Figure 5G, Figure 5---figure supplement 1). Thus, we agree that just the RNA expression profile of these OCLs is not fully supporting their immunosuppressive role. In the revised manuscript, the comment on the RNAseq analysis for this figure in the Results section has been rephrased accordingly. However, our conclusions do not only rely on the expression profile of osteoclasts, but also on in vitro functional analysis that clearly show:

1\) that the T cell activation capacity of Cx3cr1^+^ OCLs is increased when blocking the immunosuppressive checkpoint protein PD1 in vitro (Figure 6C), 2) that in an immunosuppressive assay, Cx3cr1^+^ OCLs reduce the capacity of Cx3cr1^neg^ OCLs to stimulate T cell proliferation (Figure 6D-E) which is a clear functional demonstration of their immunosuppressive effect, at least in vitro as mentioned in the revised version.

> 6\) In Figure 1 the authors claim that CXC3R1 positive osteoclasts are needed for the full bone resorbing activity of osteoclasts after ovariectomy. The claim is based on only minor differences and whether CXC3R1 positive osteoclasts were preset or not, the osteoporosis phenotype develops in an equally severe manner. Moreover, these data contradict a statement made later in the paper that CXC3R1 positive osteoclasts are not needed for bone resorption.

We agree that the differences observed when comparing OVX WT mice and OVX Cx3cr1-deficient mice (Figure 1B-C) for the microscanner analysis are minor but they are significant and are further supported by a reduced osteoclast number (Figure 1D). But to follow the reviewer concern, we rephrased the comment of this figure in the Results section to indicate this low degree of variation.

However, there might be a misunderstanding as we didn\'t claim that Cx3cr1^+^ OCLs are required for bone loss in OVX mice. Figure 1 is not addressing the role of Cx3cr1^+^ osteoclasts but the implication of the Cx3cr1 protein in bone destruction associated to ovariectomy, which are 2 different questions. In Figure 1, we showed that Cx3cr1, as a protein, is important for the recruitment of OCL progenitors in the bone marrow of OVX mice (Figure 1E-F). Moreover, we showed that i-OCLs from Cx3cr1-deficient and from WT mice have the same resorption activity (Figure 2C), which demonstrates that the protein Cx3cr1 is not important for this activity.

Moreover, we didn\'t claim that Cx3cr1^+^ OCLs are not needed for bone resorption, we only showed that they resorb less than the Cx3cr1^neg^ OCLs (Figure 4E-F).

But to avoid any misunderstanding, we modified the text to make it clearer and to describe in more details the mouse model we used. We also added in Figure 2 and 3 a schematic representation of the preparation of the cells to avoid any confusion.

> 7\) Data shown in Figure 2 (no difference in the bone resorption capacities of CX3CR1+ cells isolated from GFP/+ mice and CX3CR1- cells isolated from GFP/GFP mice) and those shown in Figure 4 (large differences in bone resorptive capacities of CX3CR1+ and CX3CR1-negative cells derived from dendricytes) are contradictory. This inconsistency calls into question the validity of using cells derived from the dendricytes in culture if they behave differently from the mature cells isolated from the genetically modified mice.

As explained in the first point above, due to methodological issues, in particular the absence of a protocol to isolate sufficient osteoclasts or to sort ex vivo specific subsets of OCLs, there is no other possibility to investigate the function of these OCLs than the use of in vitro differentiated cells. In particular in our study, all inflammatory osteoclasts used in functional assays were derived from dendritic cells in exactly the same culture conditions, as already described (Ibanez et al., 2016). Thus, even if we cannot exclude that the culture conditions could affect osteoclast function compared to in vivo, it would be to the same extend in all our analysis. It would also be to the same extend as in all studies investigating osteoclast activity published so far.

Regarding the reviewer\'s concern on potential inconsistency in our results, there might be a misunderstanding. In Figure 2, we addressed the role of Cx3cr1, as a protein, in bone resorption and T cell activation by osteoclasts. This was achieved comparing Cx3cr1^+^ osteoclasts coming either from WT (Cx3cr1^GFP/+^) mice or from mice baring a non-functional Cx3cr1 gene (Cx3cr1^GFP/GFP^). There are no data on Cx3cr1^neg^ cells in Figure 2. And indeed, we showed that Cx3cr1^+^ cells have equivalent resorption capacity whether Cx3cr1 is functional or not (Figure 2), which demonstrates that the protein Cx3cr1 is not important for this activity.

In contrast, in Figure 4, we addressed, in WT mice, the specific function of the 2 distinct subsets of osteoclasts that are identified using Cx3cr1 as a membrane marker. We showed that Cx3cr1^+^ and Cx3cr1^neg^ i-OCLs from WT mice differ in their resorption and T cell activation capacity (Figures 3-6).

Thus, Figures 1-2 and Figures 3-6 explore 2 completely distinct aspects that could not be compared.

Importantly, Cx3cr1^+^ OCLs having a non-functional *Cx3cr1* gene could not be considered equivalent to Cx3cr1^neg^ OCLs from WT mice. Indeed, as shown in [Author response image 1](#sa2fig1){ref-type="fig"}, principal component analysis of our transcriptomic data clearly demonstrated that while Cx3cr1^+^ i-OCLs from WT and mutant mice are closely related, both differ considerably from Cx3cr1^neg^ cells from WT mice as they cluster in 2 completely distinct groups (panel A). This was further confirmed by matrix similarity analysis of our transcriptomic data that showed again that the 2 populations are distinct (panel B). Therefore none of the conclusions made for one of these population can be applied to the other.

However, we recognize that switching from the analysis of the implication of the Cx3cr1 protein in bone loss to the analysis of the respective role of Cx3cr1^+^ and Cx3cr1^neg^ i-OCL could be confusing. Thus, in the revised manuscript we modified the text to make it clearer and we added schematic representations of the preparation of OCLs in the figures.

![Cx3cr1^neg^ i-OCLs from Cx3cr1^GFP/+^ mice are distinct from Cx3cr1^+^ i-OCLs from deficient Cx3cr1^GFP/GFP^ mice.\
A) Principal component analysis of Cx3cr1^+^ from deficient Cx3cr1^GFP/GFP^ mice (green) and Wt Cx3cr1^GFP/+^ mice (red) and Cx3cr1^neg^ i-OCLs from Cx3cr1^GFP/+^ mice (blue). Data shows the two first components after batch correction. Each dot represents the expression profile of one sample. B) Similarity matrix analysis on the same samples.](elife-54493-resp-fig1){#sa2fig1}
